UAE Inhibitor TAK-243

Phase 1Small molecule

NNational Cancer Institute (NCI)

UAE Inhibitor TAK-243 is one of 16 small molecule programs targeting Advanced Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced LymphomaRecruiting

Myelodysplastic Syndrome With Excess BlastsActive, not recruiting

Advanced LymphomaPhase 1

Recruiting

Myelodysplastic Syndrome With Excess BlastsPhase 1

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Advanced Lymphoma

#DrugCompanyPhaseTrials

Ibrance

Pfizer

Phase 2

3 2

Mekinist

Novartis

Phase 2

3 3

Erivedge

Roche

Phase 2

2 4

Adavosertib

AstraZeneca

Phase 2

2 5

Balversa

Johnson & Johnson

Phase 2

2 6

Vitrakvi

Bayer

Phase 2

2 7

Tagrisso

AstraZeneca

Phase 2

2 8

Sutent

Pfizer

Phase 2

2 9

M6620

AstraZeneca

Phase 2

2 10

Xalkori

PPrism Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Advanced Lymphoma

NCT06223542

Q4 2027

Phase 1Active, not recruiting

Myelodysplastic Syndrome With Excess Blasts

NCT03816319

Clinical

Trials by Indication[1]

Myelodysplastic Syndrome With Excess Blasts1 trial

A Phase 1 Study of TAK-243 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03816319·42 enrolled

Advanced Lymphoma1 trial

A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06223542·95 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for UAE Inhibitor TAK-243. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — UAE Inhibitor TAK-243 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for UAE Inhibitor TAK-243. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNational Cancer Institute (NCI)

UAE Inhibitor TAK-243

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Trials by Indication[1]

Myelodysplastic Syndrome With Excess Blasts1 trial

Advanced Lymphoma1 trial

References

Drug Info

Quick Facts

Related News